Position in BLTE
as of Mar 31, 2026
· filed Apr 17, 2026
Position Value
$637
New position
Shares Held
4
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bell Investment Advisors, Inc holds $351,465 across 64 Biotechnology names. BLTE ranks #47 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
129 | $57,603 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
1,471 | $40,746 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
44 | $33,996 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
53 | $17,536 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
223 | $16,559 | |
| 6 | INCY |
Incyte Corp
|
156 | $14,682 | |
| 7 | ARGX |
Argenx SE
|
18 | $13,144 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
177 | $11,439 |
All Filings in BLTE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $637 | 4 | Shares | Sole | 2026-04-17 | |
| No filing history on record for this holder in this stock. | ||||||